abrdn Life Sciences Investors Announces Annual Meeting of Shareholders
Ticker: HQL · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 884121
| Field | Detail |
|---|---|
| Company | Abrdn Life Sciences Investors (HQL) |
| Form Type | DEF 14A |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy statement, annual meeting, shareholder proposal, trustee election, abrdn Life Sciences Investors
TL;DR
<b>abrdn Life Sciences Investors will hold its annual shareholder meeting on June 25, 2024, to elect trustees and consider a proposal for annual trustee elections.</b>
AI Summary
abrdn Life Sciences Investors (HQL) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. Annual meeting of shareholders for abrdn Life Sciences Investors to be held on June 25, 2024. The meeting will take place at 1900 Market Street, Suite 200, Philadelphia, PA 19103. Shareholders of record as of April 1, 2024, are entitled to vote. Proposal 1: Election of two Class B Trustees for a term until the 2027 Annual Meeting. Proposal 2: Consideration of a shareholder proposal to reorganize the Board of Trustees into a single class with annual elections.
Why It Matters
For investors and stakeholders tracking abrdn Life Sciences Investors, this filing contains several important signals. The election of Class B Trustees is a standard governance procedure to ensure board continuity and oversight. The shareholder proposal regarding annual trustee elections could lead to significant changes in the fund's governance structure if approved.
Risk Assessment
Risk Level: low — abrdn Life Sciences Investors shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Shareholders should review the proxy materials carefully to understand the proposals and cast their votes accordingly.
Key Numbers
- June 25, 2024 — Annual Meeting Date (Date of the annual meeting of shareholders.)
- April 1, 2024 — Record Date (Shareholders of record on this date are entitled to vote.)
- 2027 — Trustee Term End (Year until which elected Class B Trustees will serve.)
Key Players & Entities
- abrdn Life Sciences Investors (company) — Registrant and filer of the proxy statement.
- June 25, 2024 (date) — Date of the annual meeting of shareholders.
- April 1, 2024 (date) — Record date for determining shareholders entitled to vote.
- 1900 Market Street, Suite 200, Philadelphia, PA 19103 (location) — Location of the annual meeting.
- Class B Trustees (governance) — Class of trustees to be elected.
- 2027 Annual Meeting (date) — Term end date for elected trustees.
FAQ
When did abrdn Life Sciences Investors file this DEF 14A?
abrdn Life Sciences Investors filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by abrdn Life Sciences Investors (HQL).
Where can I read the original DEF 14A filing from abrdn Life Sciences Investors?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by abrdn Life Sciences Investors.
What are the key takeaways from abrdn Life Sciences Investors's DEF 14A?
abrdn Life Sciences Investors filed this DEF 14A on April 22, 2024. Key takeaways: Annual meeting of shareholders for abrdn Life Sciences Investors to be held on June 25, 2024.. The meeting will take place at 1900 Market Street, Suite 200, Philadelphia, PA 19103.. Shareholders of record as of April 1, 2024, are entitled to vote..
Is abrdn Life Sciences Investors a risky investment based on this filing?
Based on this DEF 14A, abrdn Life Sciences Investors presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading abrdn Life Sciences Investors's DEF 14A?
Shareholders should review the proxy materials carefully to understand the proposals and cast their votes accordingly. The overall sentiment from this filing is neutral.
How does abrdn Life Sciences Investors compare to its industry peers?
abrdn Life Sciences Investors is a closed-end investment company. This filing pertains to its annual shareholder meeting and governance matters.
Are there regulatory concerns for abrdn Life Sciences Investors?
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.
Risk Factors
- Proxy Statement Filing [low — regulatory]: The filing is a routine DEF 14A proxy statement, indicating compliance with SEC filing requirements for annual meetings.
Industry Context
abrdn Life Sciences Investors is a closed-end investment company. This filing pertains to its annual shareholder meeting and governance matters.
Regulatory Implications
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.
What Investors Should Do
- Review the proxy statement for details on the nominated trustees and the shareholder proposal.
- Vote your shares by the deadline to ensure your voice is heard on governance matters.
- Consider the implications of reorganizing the Board of Trustees into a single class with annual elections.
Key Dates
- 2024-06-25: Annual Meeting of Shareholders — Shareholders will vote on trustee elections and a governance proposal.
- 2024-04-01: Record Date — Determines eligibility to vote at the annual meeting.
Year-Over-Year Comparison
This is a DEF 14A filing for the annual meeting, providing information on upcoming proposals and elections, rather than a report on financial performance.
Filing Stats: 4,641 words · 19 min read · ~15 pages · Grade level 12.4 · Accepted 2024-04-22 16:12:17
Filing Documents
- tm2410797d15_def14a.htm (DEF 14A) — 189KB
- j241079718_ba001.jpg (GRAPHIC) — 16KB
- j241079718_ba002.jpg (GRAPHIC) — 5KB
- j241079718_ba003.jpg (GRAPHIC) — 4KB
- j241079718_ba004.jpg (GRAPHIC) — 5KB
- tm2410797d15_hqlimg001.jpg (GRAPHIC) — 139KB
- tm2410797d15_hqlimg002.jpg (GRAPHIC) — 147KB
- 0001104659-24-049993.txt ( ) — 627KB
From the Filing
DEF 14A 1 tm2410797d15_def14a.htm DEF 14A   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A   SCHEDULE 14A INFORMATION   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.         )   Filed by the Registrant     [ X ]   Filed by a Party other than the Registrant     [   ]   Check the appropriate box:   [   ] Preliminary Proxy Statement [   ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ X ] Definitive Proxy Statement [   ] Definitive Additional Materials [   ] Soliciting Material under §240.14a-12   abrdn Life Sciences Investors (Name of Registrant as Specified In Its Charter)   (Name of Person(s) Filing Proxy Statement, if other than the Registrant)   Payment of Filing Fee (Check the appropriate box):   [ X ] No fee required. [   ] Fee paid previously with preliminary materials. [   ] Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11.     ABRDN LIFE SCIENCES INVESTORS 1900 Market Street, Suite 200 Philadelphia, PA 19103 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To be held on June 25, 2024 TO THE SHAREHOLDERS: NOTICE IS HEREBY GIVEN that the annual meeting of shareholders of the abrdn Life Sciences Investors (formerly, Tekla Life Sciences Investors) (the "Fund") and any adjournments or postponements thereof will be held at the offices of abrdn Inc., located at 1900 Market Street, Suite 200, Philadelphia, PA 19103 (the "Annual Meeting,") on Tuesday, June 25, 2024 at 2:00 p.m. The purpose of the Annual Meeting is to consider and act upon the following proposals (each, a "Proposal") and to consider and act upon such other matters as may properly come before the Annual Meeting or any adjournments or postponements thereof: Proposal 1: To elect two Class B Trustees to serve until the 2027 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified. Proposal 2—Elect Each Trustee Annually: To take action on a shareholder proposal requesting that the Fund take the steps necessary to reorganize the Board of Trustees into one class with each Trustee subject to election each year, if properly presented at the meeting. Each Proposal is discussed in greater detail in the enclosed Proxy Statement. You are entitled to notice of, and to vote at, the Annual Meeting if you owned shares of the Fund at the close of business on April 1, 2024 (the "Record Date"). Even if you expect to attend an Annual Meeting, please complete, date, sign and return the enclosed proxy card(s) in the enclosed postage-paid envelope or authorize your proxy by telephone or through the Internet. We will admit to an Annual Meeting (1) all shareholders of record on the Record Date, (2) persons holding proof of beneficial ownership on the Record Date, such as a letter or account statement from the person's broker, (3) persons who have been granted proxies, and (4) such other persons that we, in our sole discretion, may elect to admit. All persons wishing to be admitted to an Annual Meeting must present photo identification. If you plan to attend an Annual Meeting, we ask that you call us in advance at 1-800-522-5465. This Notice and related proxy materials are first being mailed to shareholders on or about April 22, 2024. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to Be Held on Tuesday, June 25, 2024: This Notice, the Proxy Statement and the form of proxy cards are available on the Internet at http://www.abrdnhql.com. On the Fund's website, you will be able to access the Notice, the Proxy Statement, the form of proxy card(s) and any amendments or supplements to the foregoing materials that are required to be furnished to shareholders. By order of the Boards of Trustees, Megan Kennedy, Vice President and Secretary TO AVOID THE UNNECESSARY EXPENSE OF FURTHER SOLICITATION, WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, IT IS IMPORTANT THAT YOUR SHARES BE REPRESENTED AND VOTED AT THE ANNUAL MEETING. ACCORDINGLY, YOU ARE REQUESTED TO PLEASE DATE, SIGN AND RETURN THE ENCLOSED PROXY CARD(S) FOR THE ANNUAL MEETING PROMPTLY, OR TO AUTHORIZE THE PROXY VOTE BY TELEPHONE OR THROUGH THE INTERNET PURSUANT TO THE INSTRUCTIONS ON THE ENCLOSED PROXY CARD(S). NO POSTAGE IS REQUIRED IF MAILED IN THE UNITED STATES. IT IS IMPORTANT THAT YOUR PROXY CARD(S) BE RETURNED PROMPTLY IN ORDER TO AVOID THE ADDITIONAL EXPENSE OF FURTHER SOLICITATION. April 22, 2024 Philadelphia, Pennsylvania ABRDN LIFE SCIENCES INVESTORS ("HQL") (the "Fu